One of the most valuable ways to track the efficacy of new drugs is to read clinical trial reports in peer-reviewed journals. For your convenience, we present here such articles about Alkermes' products and product pipeline.
Selected Publications
Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman B, Hausmann M, Heinemann L, Muchmore DB. 2007. AIR Inhaled Insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 30(7): 1777-82.
Rosenstock J, Nakano M, Silverman BL, Sun B, De La Peña A, Suri A, Muchmore DB. 2007. Comparison of standard (self-directed) versus intensive patient training for the Human Insulin Inhalation Powder (HIIP) Delivery System in patients with type 2 diabetes: Efficacy, safety, and training measures. Diabetes Technology & Therapeutics 9(1): 80-88.
Hayes RP, Nakano M, Muchmore D, Schmitke J. 2007. Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes Human Insulin Inhalation Powder Delivery System on patient-reported outcomes and patient evaluation of the system. Diabetes Technology & Therapeutics 9(1): 89-98.
Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Munchmore DB. 2006. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49(5): 891-899.
Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC. 2005. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. Journal of Clinical Pharmacology 45: 1259-1267.
Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS, Heinemann L, Batycky RP, Muchmore DB. 2005. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin Lispro. Diabetes Care 28: 2400-2405.
Garbutt JC, Kranzler H, O'Malley S, Gastfriend DR. 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. Journal of the American Medical Association 293(13): 1617-1625.
Johnson BA, Ait-Daoud N, Aubin HJ, van den Brink W, Guzzetta R, Lowey J, Silverman B, Ehrich E. 2004. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence. Alcoholism Clinical and Experimental Research 28(9): 1356-1361.
Edwards DA. 2002. Delivery of biological agents by aerosols. AIChE Journal 48(1): 2-6.
Bartus RT, Tracy MA, Emerich DF, Zale SE. 1998. Sustained delivery of proteins for novel therapeutic products. Science 281: 1161-1162.
Edwards DA, Ben-Jebria A, Langer R. 1998. Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology 84(2): 379-385.
Herbert P, Murphy K, Johnson O, Dong N, Jaworowicz W, Tracy MA, Cleland JL, Putney SD. 1998. A large-scale process to produce microencapsulated proteins. Pharmaceutical Research 15(2): 357-361.
Putney SD and Burke PA. Improving protein therapeutics with sustained-release formulations. 1998. Nature Biotechnology 16: 153-157.
Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276: 1868-1871.